News & Updates

Excessive intrahepatic fat deposition (IPFD) appears to contribute to an increased risk of major pancreatic disease, suggests a recent study, noting the potential benefits of IPFD reduction in preventing pancreatitis and pancreatic cancer.

Management of metastatic hormone-sensitive prostate cancer (mHSPC) continues to evolve as clinicians refine the use of androgen deprivation therapy (ADT) and/or chemotherapy in combination with androgen receptor pathway inhibitors (ARPIs) in routine clinical practice. At an advisory board meeting organized by the Hong Kong Society of Uro-Oncology, Professor Axel Merseburger of the University of Lübeck in Germany and Dr Darren Poon of the Hong Kong Sanatorium & Hospital discussed updated strategies and shared case studies to illustrate use of optimal ARPI-based regimens in patients with mHSPC.

Prostate cancer patients treated with enzalutamide plus leuprolide have a higher probability of remaining free of distant metastasis, castration resistance, symptomatic progression, and first symptomatic skeletal event (SSE) at 5 years than those treated with leuprolide alone, as shown by the results of the EMBARK study.

Treatment with ipilimumab plus nivolumab improves long-term survival in melanoma patients with asymptomatic brain metastases, according to the results of the NIBIT-M2 trial presented at AACR 2026.